Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunonutrition to Reduce Toxicities in Stage IIIA-B NSCLC
NCT03628144Phase 2Withdrawn
- Sponsor
- Moffitt Cancer Center
- Start
- Jul 2020
- Primary completion
- Sep 2022
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial (2 arms), sponsored by Moffitt Cancer Center. Primary endpoints: Incidence of Treatment Related Adverse Events Per Study Arm up to 48 months and Change in Plasma Levels of IL-6 Per Study Arm up to 48 months. Planned start Jul 2020; status: withdrawn.
Beyond the preview
Go deeper on NCT03628144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03628144.